Rani Therapeutics/$RANI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rani Therapeutics
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Ticker
$RANI
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
106
ISIN
US7530181004
Website
RANI Metrics
BasicAdvanced
$17M
-
-$0.98
-
-
Price and volume
Market cap
$17M
52-week high
$4.37
52-week low
$0.46
Average daily volume
705K
Financial strength
Current ratio
0.883
Quick ratio
0.817
Long term debt to equity
-174.687
Total debt to equity
-479.884
Interest coverage (TTM)
-10.16%
Profitability
EBITDA (TTM)
-46.548
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-2,483.25%
Operating margin (TTM)
-3,964.92%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-76.60%
Return on equity (TTM)
-1,187.52%
Valuation
Price to revenue (TTM)
12.839
Price to book
-5.58
Price to tangible book (TTM)
-5.58
Price to free cash flow (TTM)
-0.446
Free cash flow yield (TTM)
-224.22%
Free cash flow per share (TTM)
-113.90%
Growth
Earnings per share change (TTM)
-23.66%
3-year revenue growth (CAGR)
-15.10%
3-year earnings per share growth (CAGR)
-3.86%
What the Analysts think about RANI
Analyst ratings (Buy, Hold, Sell) for Rani Therapeutics stock.
RANI Financial Performance
Revenues and expenses
RANI Earnings Performance
Company profitability
RANI News
AllArticlesVideos
Rani Therapeutics Announces Research Agreement with Chugai
GlobeNewsWire·1 month ago
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update
GlobeNewsWire·1 month ago
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rani Therapeutics stock?
Rani Therapeutics (RANI) has a market cap of $17M as of June 20, 2025.
What is the P/E ratio for Rani Therapeutics stock?
The price to earnings (P/E) ratio for Rani Therapeutics (RANI) stock is 0 as of June 20, 2025.
Does Rani Therapeutics stock pay dividends?
No, Rani Therapeutics (RANI) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Rani Therapeutics dividend payment date?
Rani Therapeutics (RANI) stock does not pay dividends to its shareholders.
What is the beta indicator for Rani Therapeutics?
Rani Therapeutics (RANI) does not currently have a Beta indicator.